The early estimation of circulating drug metabolites in humans

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 8, 2012, Pages 985-997

  Luffer Atlas, Debra ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Early estimation; Human drug metabolites; Metabolite qualification strategy; Nonclinical safety assessment

Indexed keywords

DRUG; DRUG METABOLITE; LY 01; LY 05; TRACER; UNCLASSIFIED DRUG;

ATMOSPHERIC PRESSURE CHEMICAL IONIZATION; DRUG ABSORPTION; DRUG ANALYSIS; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; ELECTROSPRAY; FLUORINE NUCLEAR MAGNETIC RESONANCE; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

ANIMALS; BIOTRANSFORMATION; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; GUIDELINES AS TOPIC; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

ANIMALIA;

EID: 84864037363     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.693159     Document Type: Review

References (70)

1. The US FDA. Guidance for Industry: GUIDELINE for the Format and Content of the Nonclinical Pharmacology/Toxicology Section of an Application. Available from: Http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM079234.pdf 1987
2. Dear GJ, Beaumont C, Roberts A, et al. Approaches for the rapid identification of drug metabolites in early clinical studies. Bioanalysis 2011;3:197-213
3. Smith DA, Dalvie D. Why do metabolites circulate? Xenobiotica 2012;42:107-126
4. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 1998;50:387-412
5. Baillie TA, Cayen MN, Fouda H, et al. Drug metabolites in safety testing. Toxicol Appl Pharmacol 2002;182:188-196
6. The US FDA. Guidance for Industry: SAFETY Testing of Drug Metabolites. Available from: Http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm079266.pdf 2008
7. ICH M3(R2): GUIDANCE on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available from: Http://www.ich.org/LOB/media/MEDIA5544.pdf 2009
8. Robison TW, Jacobs A. Metabolites in safety testing. Bioanalysis 2009;1:1193-1200
9. Humphreys WG, Unger SE. Safety assessment of drug metabolites: Characterization of chemically stable metabolites. Chem Res Toxicol 2006;19:1564-1569
10. Smith DA, Obach RS. Metabolites and safety: What are the concerns, and how should we address them? Chem Res Toxicol 2006;19:1570-1579
11. Naito S, Furuta S, Yoshida T, et al. Current Opinion: Safety evaluation of drug metabolites in development of pharmaceuticals. J Toxicol Sci 2007;32:329-341
12. Leclercq L, Cuyckens F, Mannens GSJ, et al. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 2009;22:280-293
13. Smith DA, Obach RS, Williams DP, Park BK. Clearing the MIST of time: The impact of duration of administration on drug metabolite toxicity. Chem Biol Interact 2009;179:60-67
14. Smith DA, Obach RS. Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 2009;22:267-279
15. Walker D, Brady J, Dalvie D, et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 2009;22:1653-1662
16. Gross G, Wilson I. Issues in the safety testing of metabolites. Future Med Chem 2009;1:1381-1390
17. Yu H, Bischoff D, Tweedie D. Challenges and solutions to metabolites in safety testing: Impact of the International Conference on Harmonization M3(R2) guidance. Expert Opin Drug Metab Toxicol 2010;6:1539-1549
18. Anderson S, Knadler MP, Luffer-Atlas D. Overview of metabolite safety testing from an industry perspective. Bioanalysis 2010;2:1249-1261
19. Nedderman AN, Wright P. Looking back through the MIST: A perspective of evolving strategies and key focus areas for metabolite safety analysis. Bioanalysis 2010;2:1235-1248
20. Frederick CB, Obach RS. Metabolites in safety testing: "MIST" for the clinical pharmacologist. Clin Pharmacol Ther 2010;87:345-350
21. Smith DA, Obach RS. Metabolites: Have we MIST out the importance of structure and physicochemistry. Bioanalysis 2010;2:1223-1233
22. Nedderman AN, Dear GJ, North S, et al. From definition to implementation: A cross-industry perspective of past, current and future MIST strategies. Xenobiotica 2011;41:605-622
23. Davis-Bruno KL, Atrakchi A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Res Toxicol 2006;19:1561-1563
24. Atrakchi AH. Interpretation and considerations on the safety evaluation of human drug metabolites. Chem Res Toxicol 2009;22:1217-1220
25. Guengerich FP. Safety assessment of stable drug metabolites. Chem Res Toxicol 2006;19:1559-1560
26. Baillie TA. Approaches to the safety assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem Res Toxicol 2009;22:263-266
27. Pang KS. Safety testing of metabolites: Expectations and outcomes. Chem Biol Interact 2009;179:45-59
28. Obach RS, Nedderman AN, Smith DA. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: Are they still necessary? Xenobiotica 2012;42:46-56
29. Anderson S, Luffer-Atlas D, Knadler MP. Predicting circulating human metabolites: How good are we? Chem Res Toxicol 2009;22:243-256
30. Park KB, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Disc 2011;10:292-306
31. Luffer-Atlas D. Unique/major human metabolites: Why, how, and when to test for safety in animals. Drug Metab Rev 2008;40:447-463
32. Brodie BB, Gillette JR, La Du BN. Enzymatic metabolism of drugs and other foreign compounds. Annu Rev Biochem 1958;27:427-454
33. Bachmann C, Bickel MH. History of drug metabolism: The first half of the 20th century. Drug Metab Rev 1985;6:185-253
34. Axelrod J. An unexpected life in research. Annu Rev Pharmacol Toxicol 1988;28:1-23
35. Wang WW, Khetani SR, Krzyzewski S, et al. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 2010;38:1900-1905
36. Yun C-Ho, Yim S-K, Kim D-H, Ahn T. Functional expression of human cytochrome P450 enzymes in Escherichia coli. Curr Drug Metab 2006;7:411-429
37. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 1981;29:408-413
38. Gao H, Deng S, Obach RS. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. Drug Metab Dispos 2010;38:2147-2156
39. Ma S, Li Z, Lee K-J, Chowdhury SK. Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds. Chem Res Toxicol 2010;23:1871-1873
40. Marathe PH, Shyu WC, Humphreys WC. The use of radiolabeled compounds for ADME studies in discovery and exploratory development. Curr Pharm Design 2004;10:2991-3008
41. Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 2007;13:17-42
42. Solon EG, Schweitzer A, Stoeckli M, Prideaux B. Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development. AAPS J 2010;12:11-26
43. Prakash C, Shaffer CL, Tremaine LM, et al. Application of liquid chromatography-accelerator mass spectrometry to evaluate the metabolite profiles of a drug candidate in human urine and plasma. Drug Metab Lett 2007;1:226-231
44. Lappin G, Stevens L. Biomedical acceleratory mass spectrometry: Recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 2008;4:1021-1033
45. Nedderman A. The use of accelerator MS in support of MIST. Bioanalysis 2011;3:2695-2699
46. Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008;327:288-289
47. Powley MW, Frederick CB, Sistare FD, DeGeorge JJ. Safety assessment of drug metabolites: Implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s. Chem Res Toxicol 2009;22:257-262
48. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-912
49. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007;7:118-130
50. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice. Nat Biotechnol 2007;25:903-910
51. Chen AA, Thomas DK, Ong LL, et al. Humanized mice with ectopic artificial liver tissues. PNAS 2011;108:11842-11847
52. Wright P, Miao Z, Shilliday B. Metabolite quantification: Detector technology and MIST implications. Bioanalysis 2009;1:831-845
53. Kall MA, Gordon B, Laakso S, et al. Best practices in a tiered approach to metabolite qualification: Views and recommendations of the European Bioanalysis Forum. Bioanalysis 2010;2:1185-1194
54. The US FDA. Guidance for Industry: BIOANALYTICAL Method Validation. Available from: Http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070107.pdf 2001
55. EMA. Draft guideline on validation of bioanalytical methods. Available from http://www.ema.europa.eu/pdfs/human/ewp/19221709en.pdf 2009
56. Tiller PR, Yu S, Bateman KP, et al. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. Rapid Commun Mass Spectrom 2008;22:3510-3516
57. Zhu P, Tong W, Alton K, Chowdhury S. An accurate-mass-based spectral-averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC-MS data. Anal Chem 2009;81:5910-5917
58. Srivastava A, Lian L-Y, Maggs JL, et al. Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab Dispos 2010;38:122-132
59. Ellis MK, Naylor JL, Green T, Collins MA. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2- trifluoroethane (HCFC133A) in the rat by 19F-NMR spectroscopy. Drug Metab Dispos 1995;3:102-106
60. Dear GJ, Roberts AD, Beaumont C, North SE. Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J Chromatogr B Analyst Technol Biomed Life Sci 2008;876:182-190
61. Espina R, Yu L, Wang J, et al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: Implications in metabolites in safety testing. Chem Res Toxicol 2009;22:299-310
62. Walker GS, Ryder TF, Sharma R, et al. Validation of isolated metabolites from drug metabolism studies as analytical standards by quantitative NMR. Drug Metab Dispos 2011;39:433-440
63. Yu CP, Chen CL, Gorycki FL, Neiss TG. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. Rapid Commun Mass Spectrom 2007;21:497-502
64. Zhang D, Raghavan N, Chando T, et al. LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab Lett 2007;1:293-298
65. Yi P, Luffer-Atlas D. A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations. Bioanalysis 2010;2:1195-1210
66. Comezoglu SN, Ly VT, Zhang D, et al. Biotransformation profiling of [14C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). Drug Metab Pharamacokinet 2009;24:511-522
67. Cuyckens F, Pauwels N, Koppen V, Leclercq L. Use of relative 12C/14C isotope ratios to estimate metabolite concentrations in the absence of authentic standards. Bioanalysis 2012;4:143-156
68. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008;83:227-230
69. Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol 2006;217:143-152
70. NIH, DARPA and FDA collaborate to develop cutting-edge technologies to predict drug safety. Available from: Http://govhealthit.com/press-release/ nihdarpa-and-fda-collaborate-developcutting-edge-technologies-predict- drugsafety 2011